Compare YHC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | ITRM |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | YHC | ITRM |
|---|---|---|
| Price | $0.92 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 181.6K | ★ 398.6K |
| Earning Date | 11-14-2025 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,103,341.00 | $390,000.00 |
| Revenue This Year | $69.97 | N/A |
| Revenue Next Year | $403.29 | $947.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.68 | $0.26 |
| 52 Week High | $98.00 | $1.58 |
| Indicator | YHC | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 41.27 |
| Support Level | $0.80 | $0.27 |
| Resistance Level | $0.95 | $0.37 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 56.74 | 20.07 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.